Related Experiment Video
Updated: May 25, 2026

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides
1Department of Medicinal Chemistry, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria. johannes.winkler@univie.ac.at
Abstract:
The enormous promise of siRNA technology for rational and targeted therapy can only be realized if the inherent problems in terms of pharmaceutical development are overcome. Besides liposomal and polymeric nanoparticles, fusion proteins hold great potential for cell-type specific delivery of siRNA. Consisting of a protein binder and an oligonucleotide complexing domain, fusion proteins are designed for targeted delivery to a certain tissue or organ and subsequent release of the siRNA after cellular uptake. This article focuses on the possibilities and importance of targeting and complexing domains, including polymers and dendrimers. In vitro and in vivo evaluations are discussed with an in-depth view on pharmacokinetic properties. Remaining challenges concerning specificity on the tissue and molecular levels are highlighted.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

